<DOC>
	<DOCNO>NCT00145587</DOCNO>
	<brief_summary>Malignant infantile osteopetrosis ( MIOP ) rare fatal genetic disorder characterize bone 's inability regulate remodeling . The curative therapy hematopoietic stem cell transplantation . Stem cell provide HLA identical match sibling donor standard care , feasible majority patient . In addition , due potentially rapid progression disease , time identify suitable HLA match unrelated donor optimal . Therefore study design test hypothesis child osteopetrosis properly engraft hematopoietic stem cell donate partially match parental donor , `` haploidentical '' stem cell donor process investigational device , CliniMACS selection system .</brief_summary>
	<brief_title>Stem Cell Transplantation Children Affected With Osteopetrosis</brief_title>
	<detailed_description>The primary objective trial answer strictly patient enrol receive haploidentical stem cell donor graft . Patients match sibling donor offer participation clinical trial receive standard myeloablative condition regimen follow infusion unmanipulated bone marrow graft . However , data transplant recipient report descriptive manner . Secondary Objectives trial include follow : - To describe outcome child MIOP receive hematopoietic stem cell match sibling donor haploidentical donor utilize uniform approach one year transplant - To estimate fraction child MIOP genetic defect correlate osteopetrosis phenotype - To assess carrier-state genetic mutation parent affect child - To assess carrier-state genetic mutation sibling affect child - To estimate effect age time hematopoietic stem cell transplantation overall outcome child MIOP - To describe kinetics select cytokine expression transplantation</detailed_description>
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Clinical diagnosis malignant osteopetrosis document bone marrow biopsy radiographic image A suitable hematopoietic stem cell donor available Participant Carbonic Anhydrase II ( CAII ) deficiency osteopetrosis variant Symptomatic cardiac disease evidence significant cardiac dysfunction ECHO ( shorten fraction &lt; 30 % ) Creatinine clearance ≤ 40ml/min/1.73m^2 Bilirubin ≥ 3mg/dL SGPT ≥ 500 U/L Evidence current severe infection would preclude ablative chemotherapy successful transplantation Karnofsky Lansky score &lt; 70 note expect abnormality</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Osteopetrosis</keyword>
	<keyword>Autosomal recessive bone disease</keyword>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>T-cell depletion methodology</keyword>
	<keyword>Miltenyi Biotec CliniMACS stem cell selection device</keyword>
</DOC>